https://doi.org/10.4081/reumatismo.2014.799
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Submitted: 12 October 2014
Accepted: 22 December 2014
Published: 31 March 2015
Accepted: 22 December 2014
Abstract Views: 2338
PDF: 2189
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
How to Cite
Rossini, M., Viapiana, O., Orsolini, G., Fracassi, E., Idolazzi, L., Gatti, D., … Govoni, M. (2015). Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo, 66(4), 285–303. https://doi.org/10.4081/reumatismo.2014.799
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- D. Mohamadzadeh, S. Assar, M. Pournazari, P. Soufivand, S. Danaei, Disseminated cutaneous herpes simplex infection after COVID-19 vaccination in a rheumatoid arthritis patient: a case report and review , Reumatismo: Vol. 74 No. 2 (2022)
- R. Tanten Zabaleta, J. Marín, J.B. Zacariaz Hereter, J. Maritano, M. Fullana, N. Alvarado, E.R. Soriano, J.E. Rosa, Clinical utility of lung ultrasound for the detection of interstitial lung disease in patients with rheumatoid arthritis , Reumatismo: Early Access
- S. Bellissimo, M.G. Ferrucci, A. Gallo, S. Stisi, Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis , Reumatismo: Vol. 59 No. 3 (2007)
- F.M. Mariani, A. Alunno, F. Carubbi, C. Ferri, A rare case of symptomatic creatine kinase elevation in a patient with rheumatoid arthritis treated with baricitinib , Reumatismo: Vol. 76 No. 2 (2024)
- M. Skoczynska, F. Figus, V. Arena, G. Massazza, A. Iagnocco, The role of PET in a clinically silent and ultrasound negative synovitis in the course of rheumatoid arthritis - a case report , Reumatismo: Vol. 73 No. 1 (2021)
- S. Capellino, P. Montagna, B. Villaggio, M. Cutolo, Effects of estrogen peripheral metabolism in rheumatoid arthritis , Reumatismo: Vol. 57 No. 2 (2005)
- G. Bagnato, L.G. De Filippis, A. Caliri, G. De Filippis, G. Bagnato, A. Bruno, N. Gambardella, M.R. Muscatello, R. Cambria, R. Zoccali, Comparation of levels of anxiety and depression in patients with autommune and chronic-degenerative rheumatic: preliminary data , Reumatismo: Vol. 58 No. 3 (2006)
- M.A. Cimmino, EPIDEMIOLOGY OF PSORIASIS AND PSORIATIC ARTHRITIS , Reumatismo: Vol. 59 No. s1 (2007)
- M. Tasso, N. Bertolini, E. Mostacciuolo, S. Passavanti, J.M.E. Luppino, A. Del Puente, R. Peluso, F. Santelli, R. Scarpa, L. Costa, F. Caso, Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy , Reumatismo: Vol. 74 No. 3 (2022)
- D. Bonanno, R. Fedele, P. Minciullo, P. Quattrocchi, B. Ferlazzo, Idiopathic hypereosinophilic syndrome associated with rheumatoid arthritis A case report , Reumatismo: Vol. 55 No. 3 (2003)
<< < 12 13 14 15 16 17 18 19 20 21 > >>
You may also start an advanced similarity search for this article.
